Clariant has officially inaugurated its newly expanded state-of-the-art facilities at Daya Bay, China, marking the completion of its strategic CHF 80-million investment on November 6, 2025. This expansion significantly strengthens Clariant's manufacturing capabilities in pharmaceutical excipients and specialty chemicals—a development likely to have considerable impact across the Chinese and broader Asian pharmaceutical value chain. The company's upgraded Daya Bay site enhances its position as a leading supplier of specialty chemicals for both the healthcare and personal care sectors, supporting growing demand and industrial transformation in one of Asia's most dynamic markets.

The cornerstone of this expansion is a second pharmaceutical spray tower, which has been purpose-built to serve Clariant's pharmaceutical excipient customers across southern China. By adding this spray tower, Clariant secures reliable supply streams for Active Pharmaceutical Ingredients (APIs), particularly those used in laxative formulations, and excipients required for drug manufacturing. The Daya Bay facility now anchors Clariant's healthcare business in Asia, providing locally manufactured products that meet international quality standards for both domestic and export markets. Additionally, the expansion introduces a new reactor to Clariant's multi-purpose plant (MPP), enabling more versatile production of high-value specialty chemicals. Notably, this reactor facilitates manufacturing of mild surfactants for the thriving beauty industry and soil release polymers for modern home care brands, including the company's Texcare line. Such products align with consumer trends for gentle, effective ingredients and sustainable home solutions, but also enable pharmaceutical partners to access innovative technologies locally and more efficiently.

Among the technical highlights, Clariant showcases new high-performance surfactants, water-based coatings with reduced volatile organic compound (VOC) emissions, and synthetic lubricant ingredients designed to extend equipment service life. The company has also expanded its Ethylene Oxide Derivatives (EODs) production portfolio, a critical backbone for APIs, personal care, and industrial applications. The Daya Bay upgrade now supports large-volume production and collaborative innovation with local pharmaceutical and cosmetics developers, integrating tailored solutions intended to meet the region's evolving regulatory requirements and sustainability standards.

Christian Vang, Business President Care Chemicals at Clariant, emphasized, "With these expanded facilities, we are now better positioned to contribute to the health and wellbeing of Chinese consumers while supporting the growth of local industries with our innovative specialty chemicals." Vang outlined the company's long-term regional commitment, highlighting that the evolution from Clariant's first ethoxylation plant in Asia to an integrated Multi-Purpose Plant and Ethylene Oxide Derivatives site reflects years of strategic investment. "Bringing our innovation and expertise closer to customers helps drive their developments forward, addressing sustainability targets and end-product performance needs—a central priority for Asia's pharmaceutical manufacturers," he added.

The Daya Bay expansion stands to increase production capacity for pharmaceutical excipients, soil health enhancers, crop protection additives, and coatings used both in healthcare and related industries. By expanding operational capabilities, Clariant aims to collaborate closely with local clients on new product development and supply chain optimization, helping them meet rigorous pharmaceutical quality assurance standards and adapt swiftly to regulatory changes.

This strategic move comes as Asian pharmaceutical companies increasingly seek reliable specialty chemical partners, localization of critical input manufacturing, and next-generation excipient technologies to fuel innovation in drug formulation and delivery. By positioning Daya Bay as a collaborative hub, Clariant is set to play an enlarged role in China's rapid ascent as a global player in pharma manufacturing. The expansion's impact will be felt across pharmaceutical materials handling, drug formulation, packaging, and compliance, reinforcing Clariant's commitment to supporting its business customers in Asia with advanced technical capabilities and sustainable innovation.

As pharmaceutical manufacturing in China and Asia faces expansionary regulatory and market pressures, Clariant's newly opened facilities will serve as a foundation for both incremental growth and bolder innovation collaborations throughout the region.